This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Ardent Health Partners, Inc. (ARDT) and Gilead Sciences (GILD)

Tipranks - Tipranks - Tue Jun 9, 6:04AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Moderna (MRNA), Ardent Health Partners, Inc. (ARDT) and Gilead Sciences (GILD).

Introducing TipRanks MCP for Agents

Moderna (MRNA)

In a report released today, Alec Stranahan from Bank of America Securities maintained a Sell rating on Moderna, with a price target of $34.00. The company’s shares closed last Friday at $47.44, close to its 52-week low of $29.25.

According to TipRanks.com, Stranahan is a 4-star analyst with an average return of 3.9% and a 46.0% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Perspective Therapeutics, and Crispr Therapeutics AG. ;'>

Moderna has an analyst consensus of Hold, with a price target consensus of $44.76.

See today’s best-performing stocks on TipRanks >>

Ardent Health Partners, Inc. (ARDT)

Morgan Stanley analyst Craig Hettenbach maintained a Hold rating on Ardent Health Partners, Inc. today and set a price target of $12.00. The company’s shares closed last Friday at $8.68.

According to TipRanks.com, Hettenbach is ranked #2364 out of 12287 analysts.

Currently, the analyst consensus on Ardent Health Partners, Inc. is a Moderate Buy with an average price target of $12.92, a 48.0% upside from current levels. In a report issued on May 27, TipRanks – DeepSeek also downgraded the stock to Hold with a $10.00 price target.

Gilead Sciences (GILD)

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Gilead Sciences, with a price target of $165.00. The company’s shares closed last Friday at $129.16.

According to TipRanks.com, Meacham is a 5-star analyst with an average return of 9.1% and a 54.6% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Protagonist Therapeutics, and Kiniksa Pharmaceuticals. ;'>

Gilead Sciences has an analyst consensus of Strong Buy, with a price target consensus of $160.11, representing a 23.1% upside. In a report issued on May 26, Scotiabank also maintained a Buy rating on the stock with a $177.00 price target.

Read More on MRNA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).